BioAge Labs, Inc.

BioAge Labs, Inc. (BIOA) priced its initial public offering on Sep 26, 2024 at $18.00 per share, within its $17.00–$19.00 range, raising $198M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $615M. Fenwick & West advised the company and Cooley advised the underwriters.

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing treatments for metabolic diseases such as obesity by targeting the biology of human aging. Its lead candidate, azelaprag, is an orally available small molecule.

Status

IPO

Ticker

BIOA

Exchange

Nasdaq Global Select

Priced

Sep 26, 2024

IPO price

$18.00

Price range

$17.00–$19.00

Raised

$198M

Market cap at IPO price

$615M

First filed

Sep 3, 2024

Company counsel

Fenwick & West

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.